Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1375-1387

  Ligresti, Alessia ^a   Moriello, Aniello Schiano ^a,b   Starowicz, Katarzyna ^a   Matias, Isabel ^a   Pisanti, Simona ^c,d   De Petrocellis, Luciano ^b   Laezza, Chiara ^c   Portella, Giuseppe ^c   Bifulco, Maurizio ^c,d   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; CALCIUM ION; CANNABICHROMENE; CANNABIGEROL; CANNABINOID; REACTIVE OXYGEN METABOLITE; TETRAHYDROCANNABINOL; VANILLOID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL ACTIVATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; EPITHELIUM CELL; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; THYROID CELL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CALCIUM; CANNABIDIOL; CANNABINOIDS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRPV CATION CHANNELS;

EID: 33747624175     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105247     Document Type: Article

References (40)

1. Bifulco M and Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8:547-550.
2. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, and Di Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18:1606-1608.
3. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, and Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15:2745-2747.
4. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, and Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852.
5. Bornheim LM and Grillo MP (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 11:1209-1216.
6. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, and Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Investig 111:43-50.
7. Colasanti BK (1990) A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 6:259-269.
8. Contassot E, Tenan M, Schnuriger V, Pelte MF, and Dietrich PY (2004) Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93:182-188.
9. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, and Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52-56.
10. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, and Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95:8375-8380.
11. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, and Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313-319.
12. Gaoni Y and Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647.
13. Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745-755.
14. Hampson AJ, Grimaldi M, Axelrod J, and Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273.
15. Ilan AB, Gevins A, Coleman M, ElSohly MA, and de Wit H (2005) Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16:487-496.
16. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, and Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89:134-141.
17. 6 glioma cell proliferation by endogenous and synthetic cannabinoids: relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299:951-959.
18. Kogan NM (2005) Cannabinoids and cancer. Mini Rev Med Chem 5:941-952.
19. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'Argenio G, Scaglione G, Bifulco M, Sorrentini I, et al. (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125:677-687.
20. Maccarrone M, Lorenzon T, Bari M, Melino G, and Finazzi-Agro A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J Biol Chem 275:31938-31945.
21. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, and Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308:838-845.
22. McKallip RJ, Nagarkatti M, and Nagarkatti PS (2005) Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174:3281-3289.
23. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, and Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141:118-126.
24. Mechoulam R, Parker LA, and Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42 (Suppl 11):11S-19S.
25. Mimeault M, Pommery N, Wattez N, Bailly C, and Henichart JP (2003) Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56:1-12.
26. Ortar G, Ligresti A, De Petrocellis L, Morera E, and Di Marzo V (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473-1481.
27. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
28. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol, in Cannabinoids (Di Marzo V ed) pp 32-83, Kluwer Academic/Plenum Publishers, New York.
29. Rao GK and Kaminski NE (2006) Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J Pharmacol Exp Ther 317:820-829.
30. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 168:719-756.
31. Ruiz L, Miguel A, and Diaz-Laviada I (1999) Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458:400-404.
32. Russo E and Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234-246.
33. Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, and Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61:5784-5789.
34. 6 glioma cells. FEBS Lett 436:6-10.
35. Sanchez MG, Sanchez AM, Ruiz-Llorente L, and Diaz-Laviada I (2003) Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555:561-566.
36. Sarfaraz S, Afaq F, Adhami VM, and Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65:1635-1641.
37. Sarker KP, Obara S, Nakata M, Kitajima I, and Maruyama I (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 472:39-44.
38. Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C, and Bifulco M (2005) Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579:6343-6349.
39. Vaccani A, Massi P, Colombo A, Rubino T, and Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144:1032-1036.
40. Walsh D, Nelson KA, and Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137-143.